We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
A Phase I Study of Everolimus and Bendamustine in Patients With Relapsed/Refractory Lymphoid Hematologic Malignancies.
- Authors
Hoeg, Rasmus T.; Davis, Julian; Jonas, Brian A.; Tuscano, Joseph; Rosenberg, Aaron; Abedi, Mehrdad
- Abstract
<bold>Introduction: </bold>Everolimus and bendamustine both have single-agent activity against lymphoid hematologic malignancies. We examined this combination in a group of heavily pretreated patients with non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), and multiple myeloma (MM).<bold>Patients and Methods: </bold>In this phase I trial, 18 patients (8 with NHL, 6 with MM, and 4 with HL) were treated with bendamustine 90 mg/m2 on days 1 and 2 and everolimus from 5 to 10 mg daily on a 28-day cycle, for up to 4 cycles.<bold>Results: </bold>Adverse events were generally mild and mostly hematologic in nature. The most frequent grade 3/4 adverse events were lymphopenia (61%), thrombocytopenia (22%), leukopenia (22%), neutropenia (17%), and fatigue (17%). Overall response rate varied by malignancy: diffuse large B-cell lymphoma, 20% (1 of 5 patients); HL (2 of 4 patients), 50%; MM, 80% (4 of 5 patients); and indolent lymphomas, 100% (3 of 3 patients). The maximum tolerated dose of everolimus was determined to be 7.5 mg daily.<bold>Conclusion: </bold>The combination of everolimus and bendamustine appeared to be well-tolerated and relatively efficacious.
- Subjects
THERAPEUTIC use of antineoplastic agents; RESEARCH; CLINICAL trials; RESEARCH methodology; ANTINEOPLASTIC agents; MEDICAL cooperation; EVALUATION research; COMPARATIVE studies; HEMATOLOGIC malignancies; RESEARCH funding; LONGITUDINAL method; PHARMACODYNAMICS
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2020, Vol 20, Issue 7, p453
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2020.02.006